Nano Bio Technology Fardanegar (NBTF)

nbtf.ir

Nano Bio Technology Fardanegar Cooperative Company (NBTF) is a knowledge-based company active in the fields of biotechnology, nano biotechnology, and in particular the production of nano particles and pharmaceutical nano carriers. The Company Started its activities on 2014 in the field of new sciences, especially in the field of Nano Biotechnology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

news image

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More

Pharmacy Market

CORRECTING AND REPLACING SENJU PHARMACEUTICAL AND NOVALIQ ENTER INTO LICENSE AGREEMENT FOR NOV03 FOR THE TREATMENT OF DRY EYE DISEASE IN JAPAN

Businesswire | June 15, 2023

news image

Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free technology, are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for si...

Read More

Business Insights, PHARMACY MARKET

CYTEL AND GSK ADVANCE CLINICAL TRIAL DESIGN WITH SOLARA

Cytel | February 09, 2023

news image

On February 7, 2023, Cytel Inc., a provider of statistical software and advanced analytics in the life sciences industry, announced that GSK, one of the world's top biopharmaceutical firms, signed a three-year strategic agreement to increase GSK’s deployment of the clinical strategy platform Solara (R). This agreement will contribute significantly to the future development of the Solara platform. The platform can help GSK effectively align on trial goals, traverse trial uncertain...

Read More

Business Insights

EX-BIOCON TEAM SYMBIO GENERRICS COMPLETES CAPITAL RAISE FROM ASCENT CAPITAL

Symbio Generrics | November 25, 2022

news image

Symbio Generrics India Private Limited a specialized Active Pharmaceutical Ingredients & Intermediates manufacturing and marketing organization, announced that it has completed an equity capital raise from Ascent Capital, a leading growth-capital focused private equity fund. Symbio was founded by pharmaceutical professionals, Salim Shaikh and Abhijit Kale. They were soon joined by the third promoter, Akash Puranik; all of whom possess decades of experience in the global pharma...

Read More
news image

Pharmacy Market

TARSIER PHARMA RAISES CAPITAL TO EXECUTE PHASE-3 CLINICAL TRIAL

Tarsier Pharma | August 28, 2021

Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced it raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. Strategic and new investors alongside existing investors participated in this transaction. Following a successful End of Phase II meeting with the FDA, the Company obtained all necessary regu...

Read More
news image

Pharmacy Market

CORRECTING AND REPLACING SENJU PHARMACEUTICAL AND NOVALIQ ENTER INTO LICENSE AGREEMENT FOR NOV03 FOR THE TREATMENT OF DRY EYE DISEASE IN JAPAN

Businesswire | June 15, 2023

Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free technology, are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for si...

Read More
news image

Business Insights, PHARMACY MARKET

CYTEL AND GSK ADVANCE CLINICAL TRIAL DESIGN WITH SOLARA

Cytel | February 09, 2023

On February 7, 2023, Cytel Inc., a provider of statistical software and advanced analytics in the life sciences industry, announced that GSK, one of the world's top biopharmaceutical firms, signed a three-year strategic agreement to increase GSK’s deployment of the clinical strategy platform Solara (R). This agreement will contribute significantly to the future development of the Solara platform. The platform can help GSK effectively align on trial goals, traverse trial uncertain...

Read More
news image

Business Insights

EX-BIOCON TEAM SYMBIO GENERRICS COMPLETES CAPITAL RAISE FROM ASCENT CAPITAL

Symbio Generrics | November 25, 2022

Symbio Generrics India Private Limited a specialized Active Pharmaceutical Ingredients & Intermediates manufacturing and marketing organization, announced that it has completed an equity capital raise from Ascent Capital, a leading growth-capital focused private equity fund. Symbio was founded by pharmaceutical professionals, Salim Shaikh and Abhijit Kale. They were soon joined by the third promoter, Akash Puranik; all of whom possess decades of experience in the global pharma...

Read More